A Trial of GC4419 in Patients With Critical Illness Due to COVID-19

NCT04555096 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

16

Enrollment

INDUSTRY

Sponsor class

Stopped Participants are no longer receiving intervention

Conditions

Covid19
SARS-CoV-2 Infection

Interventions

DRUG: GC4419
DRUG: Placebo

Sponsor

Galera Therapeutics, Inc.